Biogen Inc. (BIIB) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
BIIB price how computed
Forward Fair Value verdict
OvervaluedBIIB is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $225.71
- Sector
- Healthcare
- 12-month range
- $147.86–$235.35
- Market cap
- $33.3B
- From 52-week high
- -4.1%
- Shares outstanding
- 148M
- Rank in Healthcare by discount to fair value
- #73 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for neurodegenerative diseases, immunology conditions, and other serious illnesses. The company operates globally with research, development, and manufacturing facilities across multiple continents, serving patients and healthcare providers worldwide.
BIIB currently ranks #73 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $33.3B
- P/E (trailing)
- 16x
- Revenue (TTM)
- $9.95B
- Net margin
- 8.4%
- EPS (TTM)
- $13.97
- Gross margin
- 56.9%
- Debt / equity
- 0.44
- Revenue growth (3-yr avg)
- 2.7%
- Shares outstanding
- 148M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 63 · neutral
- 50-day average
- $219.71
- 200-day average
- $197.83
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-10-28 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+18.4%)
2026-03 ▲ beat (+23.5%)
2025-12 ▲ beat (+22.8%)
2025-09 ▲ beat (+24.0%)
2025-06 ▲ beat (+41.0%)
2025-03 ▲ beat (+2.4%)
2024-12 ▲ beat (+2.4%)
2024-09 ▲ beat (+7.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 22 buy · 12 hold · 1 sell (35 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $244
- Target vs last price
- +8.1%
What our data shows for BIIB
- Our model validated 17 trailing price-to-earnings windows for BIIB, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $147.86–$235.35.
- The 14-day relative strength index sits at a neutral 63.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BIIB
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BIIB news
TickrTrends' derived news-sentiment signal for BIIB is currently leaning positive, computed from recent coverage.
- Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (zacks.com, 2026-10-21)
TickrTrends take: Biogen is expected to exceed its Q3 earnings estimates according to the headline, which could provide fundamental support for the stock's current valuation metrics. However, TickrTrends currently classifies BIIB as overvalued within the Healthcare sector, suggesting that positive earnings results may already be reflected in the stock's price. Valuation-focused investors should monitor whether the company's actual earnings beat is substantial enough to justify the current overvalued assessment, or whether the stock remains disconnected from underlying financial performance. - A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10 (gurufocus.com, 2026-10-20)
TickrTrends take: Biogen's recent appreciation has widened the gap between its trading price and the GF Value estimate, reinforcing TickrTrends' assessment that the stock trades at a premium to intrinsic value. A valuation-focused investor monitoring this Healthcare sector name should observe whether the company can deliver earnings growth substantial enough to justify the current market price, as the spread between valuation and price creates limited margin for error. The divergence suggests that further gains would increasingly depend on fundamental business performance rather than multiple expansion. - BIIB Maintains by Wells Fargo -- Price Target Raised to $310 (gurufocus.com, 2026-10-20)
TickrTrends take: Wells Fargo's price target increase to $310 for BIIB comes as TickrTrends currently assesses the stock as overvalued within the Healthcare sector. A valuation-focused reader should monitor whether this analyst action signals a shift in market consensus that could narrow the gap between current market pricing and intrinsic value estimates, or whether the stock remains stretched relative to fundamental measures. The divergence between analyst price targets and valuation models in the Healthcare space warrants continued attention to earnings reports and pipeline developments that could inform whether the overvaluation thesis holds.
More BIIB news
- Biogen Stock: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade) (NASDAQ:BIIB) (seekingalpha.com, 2026-10-16)
- Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? (insidermonkey.com, 2026-10-13)
- Market Alert: Strait of Hormuz Tensions Escalate as Starbucks Quashes Chipotle Merger Rumors (thestockmarketwatch.com, 2026-10-12)
- Biogen (BIIB) Shares Rise 2.1% Premarket After JPMorgan Upgrade to Overweight (gurufocus.com, 2026-10-12)
What people are saying
Follow the BIIB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — # BIIB Weekly Indicator Summary TickrTrends' derived indicators for BIIB shifted this week as the stock's valuation verdict moved from Overvalued to Fairly valued. This change reflects a reassessment of the healthcare company's valuation metrics relative to its fundamentals. The stock currently trades at levels that appear more aligned with its underlying business value.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — BIIB's valuation assessment shifted this week as the DCF cross-check band moved from fairly valued to overvalued, while the overall current valuation verdict remains at fairly valued. This divergence between the two measures suggests the stock's fundamental value estimate has increased relative to its market price according to discounted cash flow analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BIIB stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), BIIB is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is BIIB's TickrTrends verdict?
BIIB's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does BIIB compare to other Healthcare stocks?
BIIB ranks #73 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is BIIB overbought or oversold?
BIIB's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does BIIB report earnings next?
BIIB's next earnings report is scheduled for 2026-10-28 (pre-market), per the published earnings calendar.
Does BIIB usually beat earnings estimates?
Over its last 8 reported quarters BIIB beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BIIB?
Of 35 analysts covering BIIB, 22 rate it a buy, 12 a hold and 1 a sell - buy-leaning, with a consensus price target of $244 (+8.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
BIIB vs ACAD · BIIB vs BMY · BIIB vs CAH · BIIB vs CNC · BIIB vs GMAB